News

UroToday23h
ASCO 2025: Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cancer: Results of the SUNNIFORECAST Trial and Potential Role of the CPS Score and Tumor Nephrectomy
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
UroToday23h
ASCO GU 2025: STARLITE 2: Phase 2 Study of Nivolumab Plus 177lutetium-Labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in ...
ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...
UroToday23h
ASCO 2025: Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer
ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT), SWOG 8710 trial, PURE-01 trial, NIAGARA trial, ABACUS trial, CheckMate 274 trial, ImVigor 010, atezolizumab, ...